California 2019-2020 Regular Session Status: In Committee

AB 3095 — Health care practitioners: stem cell therapy.

Last action — Referred to Com. on B. & P.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Assembly
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2019-2020 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Existing law provides for the licensure and regulation of various health care practitioners by boards within the Department of Consumer Affairs. Existing law requires licensed health care practitioners who perform stem cell therapies that are subject to regulation by the United States Food and Drug Administration (FDA) , and that are not FDA approved, to communicate to their patients specified information regarding the therapies in a notice and in writing prior to providing the initial stem cell therapy. Existing law exempts from these requirements a health care practitioner who has obtained clearance for an investigational new drug, or an investigational device exemption, from the FDA. Existing law authorizes the licensing board having jurisdiction over the health care practitioner to cite and fine the health care practitioner for violation of these provisions. This bill would additionally require a health care practitioner to include in all print and digital advertising materials, including internet websites, that the administration of stem cell therapies by the health care practitioner is not FDA approved. The bill would specify that it does not apply to research being conducted under the California Stem Cell Research and Cures Act.

Bill Text

What changed in the latest version

1 added · 1 removed

1 line(s) added, 1 removed.

→
Previous
Latest
Bill Number Bill Keyword Home Bill Information California Law Publications Other Resources My Subscriptions My Favorites Bill Information >> Bill Search >> Text Bill TextBill Information PDF2 Bill PDF |Add To My Favorites | Version:
Bill Number Bill Keyword Home Bill Information California Law Publications Other Resources My Subscriptions My Favorites Bill Information >> Bill Search >> Text Bill Text PDF2 Bill PDF |Add To My Favorites | Version:
⬇ Download PDF
View plain text versions (2)

Action History

  1. Referred to Com. on B. & P.

  2. Read first time.

  3. From printer. May be heard in committee March 23.

  4. Introduced. To print.

Sponsors

  • Mullin · Primary

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 121 not signed on

Sponsors (1)

  • Mullin

Co-sponsors (0)

None.

Not signed on (121)

121 members have not signed on to this bill.

Show all 121 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does AB 3095 do?
Existing law provides for the licensure and regulation of various health care practitioners by boards within the Department of Consumer Affairs. Existing law requires licensed health care practitioners who perform stem cell therapies that are subject to regulation by the United States Food and Drug Administration (FDA) , and that are not FDA approved, to communicate to their patients specified information regarding the therapies in a notice and in writing prior to providing the initial stem cell therapy. Existing law exempts from these requirements a health care practitioner who has obtained clearance for an investigational new drug, or an investigational device exemption, from the FDA. Existing law authorizes the licensing board having jurisdiction over the health care practitioner to cite and fine the health care practitioner for violation of these provisions. This bill would additionally require a health care practitioner to include in all print and digital advertising materials, including internet websites, that the administration of stem cell therapies by the health care practitioner is not FDA approved. The bill would specify that it does not apply to research being conducted under the California Stem Cell Research and Cures Act.
Who sponsors AB 3095?
AB 3095 is sponsored by Mullin.
What is the current status of AB 3095?
This bill died with 2019-2020 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track AB 3095?
Track AB 3095 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on AB 3095

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of AB 3095

Last checked for changes 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →